By the Peptevity Research Desk — vendor-neutral, evidence-graded. Scientific review: independent reviewer pending — how our review works.

BPC-157 vs TB-500: An Evidence-Graded Comparison

Direct answer

BPC-157 and TB-500 are the two compounds marketed together as the "wolverine stack." BPC-157 is a synthetic 15-amino-acid peptide based on a sequence found in gastric juice (PMC7096228); TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) copying the actin-binding region of the 43-amino-acid protein thymosin β4 (Esposito et al., 2012). Both are studied for soft-tissue repair, and for both the evidence is animal-dominant with no human randomized controlled trials as of June 2026 (BPC-157 narrative review, 2025, PMC12446177). Neither is FDA-approved; both were removed from the FDA's interim 503A Category 2 list in April 2026 (removal is not approval) and both are scheduled for the July 23–24, 2026 Pharmacy Compounding Advisory Committee review (Federal Register, docket FDA-2025-N-6895). Both are prohibited at all times by WADA. The "stack" itself is a marketing construct, not a clinically validated combination.

This page is research and educational information, not medical advice. It compares two research compounds that are sold "research use only — not for human consumption." Neither is proven in humans, and neither is FDA-approved. Peptevity sells nothing, recommends no product or vendor, and publishes no dosing or self-administration instructions. For the dated, living status of every compound here, see the 2026 regulatory tracker, which is our source of record, and our medical disclaimer and RUO statement.

Why people compare these two

The comparison exists because of a nickname. Online sellers and wellness clinics pair BPC-157 with TB-500 and market the duo as the "wolverine peptide" stack — borrowing the Marvel character's rapid-healing reputation to imply fast, comprehensive tissue repair. The pitch is that the two peptides hit healing from different angles: BPC-157 for localized gut, tendon, and ligament repair, TB-500 for systemic, whole-body recovery and angiogenesis.

That division of labor is a tidy marketing story. It is not something a human trial has tested. There is no published randomized controlled trial of either compound alone for musculoskeletal healing in people, and there is certainly no trial of the two together (PMC12446177). So this page does what the marketing does not: it lines the two compounds up side by side, grades each claim by species and study type per our evidence-grading methodology, and states plainly where the evidence stops. The honest one-line summary up front: these are two preclinical research compounds with overlapping reputations and a shared regulatory cloud, not two proven medicines you can rank.

The verdict table

The fastest way to read the comparison is the table. Every cell is qualified below it; the grades (A–F) follow our evidence scale, where a human RCT earns a high grade and animal-only data is capped at C.

BPC-157 TB-500
What it is Synthetic 15-amino-acid peptide ("body protection compound 157"); a partial sequence of a protein reported in gastric juice (PMC7096228) Synthetic 7-amino-acid fragment, Ac-LKKTETQ (the 17–23 region of thymosin β4); not the full 43-AA thymosin β4 protein (Esposito et al., 2012)
Origin First described 1993, University of Zagreb (Sikirić et al.); made by chemical synthesis (PMC7096228) Derived from thymosin β4, an endogenous actin-sequestering peptide released by platelets at injury sites (Goldstein et al., 2012, PMID 22074294)
Proposed mechanism Cytoprotection and angiogenesis; in animals, associated with growth-factor and nitric-oxide pathway effects supporting tissue repair (Grade D, mechanistic) (PMC8275860) Sequesters G-actin to drive cell migration; thymosin β4 activates ILK/Akt survival signaling in cardiac models (Grade D, mechanistic) (Bock-Marquette et al., Nature 2004, PMID 15565145)
Most-studied for Tendon, ligament, muscle, bone, skin, and gut repair in injury models (PMC8275860) Dermal wound healing, corneal repair, and cardiac/vascular repair in injury models (Goldstein et al., 2012, PMID 22074294)
Best evidence Animal-only for healing (Grade C); three small uncontrolled human pilots; no human RCTs (PMC12446177) Animal-only for the TB-500 fragment (Grade C); human Phase 2 trials used the full thymosin β4 protein (RGN-259/RGN-137), not TB-500 — a distinct molecule (Kleinman & Sosne, 2016, PMID 27450738)
Human RCTs? None as of 2026-06-10 (PMC12446177) None for the TB-500 fragment as of 2026-06-10 (TB-500 / thymosin β4 doping characterization, 2012)
Safety in humans Largely unstudied; FDA flagged immunogenicity and impurity risks; pilot studies too small to characterize (FDA bulks safety-risks list; PMC12446177) Largely unstudied for the fragment; full-protein trials reported it well-tolerated, but that is a different molecule and product (Kleinman & Sosne, 2016)
FDA status (2026) Not approved; removed from interim 503A Category 2 in April 2026 (not approval); July 23–24, 2026 PCAC review (Federal Register, FDA-2025-N-6895) Not approved; same April 2026 removal and same July 23–24, 2026 PCAC review group (Federal Register, FDA-2025-N-6895)
WADA status Prohibited at all times under S0 (Non-Approved Substances) (WADA 2022 Prohibited List) Prohibited at all times under S2 (Peptide Hormones, Growth Factors) as a thymosin-β4 derivative (WADA Prohibited List)
Sold as "Research use only — not for human consumption" "Research use only — not for human consumption"

The table's punchline is the row called Human RCTs? Both cells say none. That single row is more decisive than every other difference between the two compounds, and the rest of this page explains why.

Origin and structure: a gut peptide vs an actin-binding fragment

The two compounds come from genuinely different biology.

BPC-157 is a pentadecapeptide — 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) — corresponding to a partial sequence of "body protection compound," a protein reported in mammalian gastric juice. It was first described in 1993 by Predrag Sikirić, Sven Seiwerth, and colleagues at the University of Zagreb, and the modern material is made by chemical synthesis (PMC7096228). It does not exist as a discrete circulating molecule in the body; it is a designed fragment.

TB-500 is where the comparison gets a wrinkle that most stack marketing erases. TB-500 is a synthetic 7-amino-acid peptide, N-terminally acetylated, sequence Ac-LKKTETQ — corresponding to residues 17–23 of thymosin β4, the actin-binding motif of that 43-amino-acid endogenous protein (Esposito et al., Drug Testing and Analysis, 2012). Thymosin β4 itself is a real, endogenous repair molecule, released by platelets at sites of injury (Goldstein et al., 2012, PMID 22074294). TB-500 is a short fragment built around its active site — chemically related to thymosin β4, but not the same molecule, a distinction we return to under evidence because it changes how the human data should be read.

So: BPC-157 is a designed gut-derived peptide; TB-500 is a designed fragment of a natural repair protein. Different lineages, similar marketing destination.

Mechanism: both plausible, both graded D

Neither compound's mechanism is established by human outcomes; both are inferred from animal and cell work. We grade the mechanism claims D (mechanistic / in-vitro) for each, even where downstream animal healing claims earn a C.

  • BPC-157. Animal and cell studies associate BPC-157 with angiogenesis (new blood-vessel formation), growth-factor signaling, and nitric-oxide-pathway effects that plausibly support tissue protection and repair (PMC8275860). The original program framed it as a cytoprotective agent centered on the gastrointestinal tract.
  • TB-500 / thymosin β4. The parent protein's defining biochemistry is G-actin sequestration — binding monomeric actin to regulate cytoskeletal dynamics, which drives cell migration in wound repair. In a landmark mouse study, thymosin β4 formed a complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt and improving cardiac function after coronary artery ligation (Bock-Marquette et al., Nature 2004, PMID 15565145). Whether the 7-residue TB-500 fragment fully reproduces the parent protein's signaling in vivo is itself not well-characterized.

Both mechanisms are biologically reasonable. That is exactly why researchers expected benefit — and exactly why mechanism alone cannot stand in for a clinical outcome.

The evidence, side by side — and why both are capped at Grade C

This is the section the stack marketing most needs you to skip.

BPC-157 — animal-dominant, three tiny human pilots, no RCTs

BPC-157's reputation rests overwhelmingly on animal research, predominantly in rats, where it was associated with faster healing of tendon, ligament, muscle, bone, skin, and gut tissue across a range of injury models (PMC8275860). A 2025 narrative review of BPC-157 for musculoskeletal healing found that, to the authors' knowledge, only three human studies have ever been published — all small, uncontrolled pilots (reported as roughly n=2, n=12, and n=12) — and no randomized controlled trials exist in humans (PMC12446177). A separate 2025 systematic review identified 35 preclinical animal studies against just one clinical study, and noted that essentially every published study reported positive effects — a pattern that raises the possibility of publication bias (PMC12313605). Verdict for BPC-157: Grade C (animal-only) for healing; the human signal is too thin to grade above E.

TB-500 — animal-dominant, and the human trials used a different molecule

TB-500's evidence picture has the same shape with an important twist. Preclinical studies of thymosin β4 report accelerated dermal wound healing across multiple animal models — normal rats and mice, steroid-treated rats, diabetic mice, and aged mice — plus corneal and cardiac repair signals (Kleinman & Sosne, Vitam Horm 2016, PMID 27450738; Goldstein et al., 2012, PMID 22074294).

Here is the twist the "stack" pitch hides: the human clinical trials that exist in this space — RegeneRx's Phase 2 programs for pressure ulcers, venous stasis ulcers, and dry-eye disease (RGN-137, RGN-259) — used the full-length 43-amino-acid thymosin β4 protein, not the 7-residue TB-500 fragment that is sold as a research peptide (Kleinman & Sosne, 2016, PMID 27450738). The TB-500 fragment itself has no completed, published human RCTs for tendon, ligament, or muscle repair; much of the peer-reviewed literature on TB-500 specifically concerns how to detect it as a doping agent (Esposito et al., 2012). So citing "thymosin β4 reached Phase 2 trials" as evidence for TB-500 is a molecule swap. Verdict for TB-500: Grade C (animal-only) for the fragment; human-trial data belongs to the related full protein, a different product.

The shared bottom line on evidence

Strip away the differences and the two compounds land in the same place: promising in animals, unproven in humans, no RCTs. That is why a side-by-side "which one works better?" cannot be answered from the evidence. You cannot rank two compounds on human efficacy when neither has been tested in a human efficacy trial. For why a strong rodent literature is still only a C, see our explainer on animal versus human peptide evidence.

Safety: largely unstudied for both, with different specifics

Safety and evidence grade are separate axes; a plausible mechanism does not imply a characterized safety profile.

  • BPC-157. The published human pilots reported no adverse effects, but they were tiny and uncontrolled and cannot characterize a human safety profile (PMC12446177). Regulators have been pointed: the FDA cited immunogenicity and impurity risks when it placed BPC-157 in Category 2 in 2023, and the U.S. Department of Defense's Operation Supplement Safety program states there is "little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans," flagging product-quality and contamination concerns (FDA bulks safety-risks list; DoD OPSS).
  • TB-500. The fragment's human safety is essentially uncharacterized. The full-protein trials (a different molecule) reported their formulations were safe and well-tolerated at the doses tested, with no drug-related serious adverse events — but those data describe the full thymosin β4 product, not the TB-500 research peptide, and cannot be transferred to it (Kleinman & Sosne, 2016, PMID 27450738).

A safety concern common to both is the gray-market product itself. Material sold as research-grade BPC-157 or TB-500 is not made under Good Manufacturing Practice, is not batch-tested for identity, potency, or purity, and carries no adverse-event reporting obligation. A clean result in a monitored study says nothing about an unregulated vial of uncertain origin. We do not issue a blanket "just don't"; we state the sourced picture — human safety for both is largely unstudied, and the unregulated supply adds its own risks. Peptevity publishes no dosing or self-administration instructions for any compound; for the framing, see what "research use only" means.

Regulatory status: a shared cloud, one small difference

Both compounds sit in nearly the same regulatory position as of June 2026 — which is one more reason "stacking" them changes nothing about their legal standing.

  • Neither is FDA-approved for any indication, and no approved drug product exists for either (FDA — bulk drug substances under 503A).
  • Both were removed from the interim 503A Category 2 list in April 2026 (effective on or about April 22, 2026) after the supporting nominations were withdrawn. Removal is not approval and is not authorization to compound — it moved both into a transitional state pending review (Federal Register, docket FDA-2025-N-6895).
  • Both are in the same July 23–24, 2026 PCAC group. The Pharmacy Compounding Advisory Committee meeting (docket FDA-2025-N-6895) considers whether to move seven peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP (emideltide), epitalon, and Semax — toward the 503A bulks list (FDA Pharmacy Compounding Advisory Committee; Federal Register, FDA-2025-N-6895). The outcome is not decided as of this review date.
  • The one difference is the WADA listing. Both are prohibited at all times in sport, but under different sections: BPC-157 under S0 (Non-Approved Substances) (WADA 2022 Prohibited List), and TB-500 under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a thymosin-β4 derivative (WADA Prohibited List). For an athlete the practical effect is identical — both trigger sanctions — but the classification differs because TB-500 maps to a recognized growth-factor family while BPC-157 is caught by the non-approved catch-all.

Because this lane is moving — a single PCAC hearing in July 2026 could change the compounding status of both at once — the date matters. We review this page on the same cadence as our living 2026 regulatory tracker, which is the source of record; any status change is logged under our corrections policy. For the broader framing, see whether peptides are legal and the difference between investigational and approved compounds.

Honest verdict: what the evidence does — and does not — support

What the evidence supports. Both BPC-157 and TB-500 (or, for TB-500, its parent protein thymosin β4) have a real, substantial preclinical literature associating them with faster tissue repair in animal models. BPC-157's animal work centers on tendon, ligament, muscle, bone, skin, and gut; thymosin β4's centers on dermal, corneal, and cardiac/vascular repair. The mechanisms — angiogenesis and cytoprotection for BPC-157, actin-binding-driven cell migration for thymosin β4 — are biologically plausible and consistently reported in animals (Grade C–D).

What the evidence does not support. It does not support any human efficacy claim for either compound. There are no human randomized controlled trials of BPC-157, and none of the TB-500 fragment; the human trials people cite for "TB-500" actually used the full thymosin β4 protein, a different molecule and a different product. It does not support ranking one above the other for people, because you cannot compare two compounds on human outcomes that have never been measured. And it does not support the "wolverine stack" as anything more than a marketing construct — there is no trial of the combination, no evidence the two are synergistic, and no approved use for either.

So the accurate answer to "BPC-157 vs TB-500 — which is better?" is that the question imports a premise the evidence rejects. Both are research compounds: promising in animals, unproven in humans, not FDA-approved, prohibited in sport, and sold "research use only — not for human consumption." If the stack marketing collapses that into "two healing peptides, pick one or take both," read this page as the correction.

For the full per-compound write-ups, see the complete BPC-157 monograph and the TB-500 monograph; for where the nickname comes from, see the wolverine peptide explained; and for the category context, the overview of peptides for health and longevity and whether peptides are safe.

Frequently asked questions

What is the difference between BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid peptide based on a sequence found in gastric juice, studied in animals mostly for gut, tendon, and ligament repair (PMC7096228). TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) of the protein thymosin β4, studied in animals mostly for dermal, corneal, and cardiac repair (Esposito et al., 2012). For both, the evidence is animal-dominant with no human randomized controlled trials as of June 2026 (PMC12446177).

Which is better, BPC-157 or TB-500? The evidence cannot answer that. Neither compound has a human efficacy trial, so there is no basis to rank them for people — both are capped at Grade C (animal-only) (PMC12446177). Anyone claiming one is proven superior in humans is going beyond the data.

Is the "wolverine stack" of BPC-157 and TB-500 proven to work? No. The "wolverine stack" is a marketing construct. There is no published human trial of either compound alone for musculoskeletal healing, and none of the two combined; no evidence establishes that they are synergistic (PMC12446177). For the nickname's origin, see the wolverine peptide explained.

Does TB-500 have human clinical trials? The TB-500 fragment does not have completed, published human RCTs. The human Phase 2 trials in this space (RegeneRx's pressure-ulcer, venous-stasis, and dry-eye programs) used the full-length thymosin β4 protein, a distinct molecule and product, not the TB-500 research peptide (Kleinman & Sosne, 2016, PMID 27450738; Esposito et al., 2012).

Are BPC-157 and TB-500 legal or FDA-approved? Neither is FDA-approved. Both were removed from the FDA's interim 503A Category 2 list in April 2026 (removal is not approval) and both are scheduled for the July 23–24, 2026 Pharmacy Compounding Advisory Committee review (Federal Register, FDA-2025-N-6895). Both are prohibited at all times by WADA — BPC-157 under S0, TB-500 under S2 (WADA Prohibited List) — and both are sold "research use only — not for human consumption." See the dated 2026 regulatory tracker.

How we graded this page

Every claim above is tied to its strongest primary source and labeled by species and study type, per our evidence-grading methodology and sourcing and citation policy. This is a comparison page; for the dated regulatory status of every compound mentioned, the 2026 regulatory tracker is the source of record. Peptevity carries no advertising, no affiliate links, and sells nothing — see our conflict-of-interest and funding statement.

Primary sources

External references appear as citations only; none of the cited institutions endorse, review, or are affiliated with Peptevity.

Related on Peptevity

Every claim above is cited inline to a primary source. See how we grade evidence and our sourcing & citation policy.